This mouse anti-BCL-2 monoclonal antibody is specific to human Bcl-2. BCL-2 monoclonal antibody recognizes the expressed product of the BCL2 gene. Bcl-2 is a widely studied modulator of programmed cell death (apoptosis) in lymphoid cells. Overexpression of the Bcl-2 protein has been shown to prevent or delay many forms of programmed cell death induced by a variety of different stimuli, including growth factor deprivation, gamma-irradiation, glucocorticoids, and chemotherapeutic agents. Validated applications for BCL-2 monoclonal antibody are immunofluorescence, immunoprecipitation, Western blotting, and immunohistochemistry.
• Applications: Validated applications for BCL-2 monoclonal antibody are immunofluorescence, immunoprecipitation, Western blotting, and immunohistochemistry.
• Host Species and Isotype: The host species and isotype of the BCL-2 monoclonal antibody is mouse IgG1κ.
• Clone ID of Monoclonal Antibody (mAb): The BCL-2 monoclonal antibody clone is Bcl-2-100.
• Reactivity: This BCL-2 monoclonal antibody detects human BCL-2.
• Product Size: BCL-2 monoclonal antibody is available in 1 mL pack size.
Bcl-2 is a widely studied modulator of programmed cell death (apoptosis) in lymphoid cells. This 26 kD integral membrane protein has been localized to several distinct subcellular locations including: the outer mitochondrial membrane, perinuclear membrane and the smooth endoplasmic reticulum. Overexpression of the Bcl-2 protein has been shown to prevent or delay many forms of programmed cell death induced by a variety of different stimuli including: growth factor deprivation, g-irradiation, glucocorticoids, and chemotherapeutic agents. The bcl-2 proto-oncogene was first identified at the breakpoint region of the t chromosomal translocation found in a large percentage (85%) of human follicular B-cell lymphomas. This translocation results in transcriptional dysregulation of the bcl-2 gene and overexpression of the Bcl-2 protein. Originally, expression of the Bcl-2 protein was thought to be restricted to neoplastic cells in which the t(14;18) chromosomal translocation was present. However, subsequent studies demonstrated that Bcl-2 is in fact expressed in both normal T- and B-cells, as well as in a variety of lymphoproliferative disorders in which the t translocation is not present. Interestingly, expression of the Bcl-2 protein has been found to be regulated in a stage-specific manner during lymphoid development and is thought to be a survival signal for positive selection. However, the precise mechanism whereby Bcl-2 acts to inhibit programmed cell death remains to be elucidated.